ABVD Shows Higher Progression-free Survival in Hodgkin Lymphoma

Share this content:
Patients with advanced Hodgkin lymphoma treated with BEACOPP or CEC did not show a progression-free survival.
Patients with advanced Hodgkin lymphoma treated with BEACOPP or CEC did not show a progression-free survival.

Patients with advanced Hodgkin lymphoma treated with BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) did not show a progression-free survival (PFS) when compared with patients treated with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine), according to a study published in the Journal of Clinical Oncology.1

Investigators conducted a post-hoc analysis of the HD2000 trial, which compared 6 cycles of ABVD, 4 escalated plus 2 standard cycles of BEACOPP, and 6 cycles of COPP-EBV-CAD (cyclophosphamide, lomustine, vindesine, melphalan, prednisone, epidoxorubicin, vincristine, procarbazine, vinblastine, and bleomycin; CEC) in patients with advanced stage Hodgkin lymphoma.

The study included 295 evaluable patients. After a median follow-up of 10 years, results showed that the 10-year PFS was highest in the CEC arm (76%), followed by BEACOPP (75%), and ABVD arm (69%). Overall survival results were 86%, 84%, and 85%, respectively.

Out of the 13 second malignancies reported, 1 occurred in the ABVD arm and 6 occurred in each the BEACOPP and CEC arms.  

The authors concluded that although patients treated with ABVD, BEACOPP, or CEC had similar overall survival results, longer follow-up did not show a PFS advantage with BEACOPP when compared with ABVD. These results were attributed to higher mortality rates due to second malignancies after treatment with BEACOPP and CEC.

Reference

  1. Merli F, Luminari S, Gobbi PG, et al. Long-term results of the HD2000 trial comparing ABVD versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: a study by Fondazione Italiana Linfomi [published online ahead of print on December 28, 2015]. J Clin Oncol. doi: 10.1200/JCO.2015.62.4817.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters